Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 30,941 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 30,941 shares of the stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $14.66, for a total value of $453,595.06. Following the completion of the sale, the chief operating officer owned 395,146 shares of the company’s stock, valued at $5,792,840.36. The trade was a 7.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Monday, April 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.55, for a total value of $277,323.00.
• On Thursday, April 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.18, for a total transaction of $270,270.80.
• On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.15, for a total transaction of $250,639.00.
• On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.77, for a total transaction of $243,396.20.
• On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total transaction of $258,453.60.
• On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total transaction of $458,855.03.
• On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total transaction of $275,417.00.
• On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total transaction of $263,599.80.
• On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.37, for a total transaction of $254,832.20.
• On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.18, for a total transaction of $251,210.80.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ ADPT traded down $0.37 during mid-day trading on Tuesday, reaching $14.21. The company had a trading volume of 1,531,229 shares, compared to its average volume of 2,018,671. Adaptive Biotechnologies Corporation has a twelve month low of $6.90 and a twelve month high of $20.76. The stock has a market capitalization of $2.19 billion, a PE ratio of -35.52 and a beta of 2.29. The stock’s 50 day moving average is $14.63 and its 200-day moving average is $16.01.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same period in the prior year, the business posted ($0.23) earnings per share. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.5 EPS for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several hedge funds have recently bought and sold shares of ADPT. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies during the fourth quarter worth $28,000. Sound Income Strategies LLC bought a new stake in Adaptive Biotechnologies during the third quarter valued at about $30,000. EverSource Wealth Advisors LLC boosted its holdings in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after acquiring an additional 1,565 shares during the period. Assetmark Inc. boosted its holdings in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. bought a new stake in Adaptive Biotechnologies during the fourth quarter valued at about $51,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ADPT has been the topic of a number of research reports. BTIG Research upped their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. JPMorgan Chase & Co. increased their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.